Takuya Nagano

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa et al. · Cancer Medicine · 2019 · 159 citations · Full text

Medicine, Oncology, Pharmacology +13

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima et al. · ESMO Open · 2022 · 130 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 129 citations · Full text

Medicine, Oncology, Pharmacology +15

Cytokine Profile in the Liver of Primary Biliary Cirrhosis

Takuya Nagano, Kazuhide Yamamoto, Seiji Matsumoto et al. · Journal of Clinical Immunology · 1999 · 108 citations

Medicine, Immunology, Pathology +14

Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka et al. · Liver International · 2020 · 97 citations · Full text

Medicine, Oncology, Pharmacology +11